Evidence map›Paper›PMID 28956218›Full record

ArticlePharmaceutical research2017

Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.

Hitesh S Purohit, Lynne S Taylor

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. A novel amorphous solid dispersion based on drug-polymer complexation.Drug delivery and translational research · 2021
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hitesh S PurohitDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana, 47907, USA.
Lynne S TaylorDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana, 47907, USA. lstaylor@purdue.edu.ORCID http://orcid.org/0000-0002-4568-6021
Purdue University West Lafayette · US

Funding

AFM based nanoscale IR Spectroscopy (AFM-IR) as a characterization platform for PR42GM100657 · NIGMS · ANASYS INSTRUMENTS CORPORATION · PI TAYLOR, LYNNE S · 2015 to 2016
$977k
Development of a new Imaging Platform for Pharmaceutical and Biomedical applicatiR41GM100657 · NIGMS · ANASYS INSTRUMENTS CORPORATION · PI TAYLOR, LYNNE S · 2012 to 2012
$230k
Directorate for Engineering EEC-0540855National Institute of General Medical Sciences GM100657-03
6 · The paper itself

Abstract

purposeThe aim of this research was to study the interplay of solid and solution state phase transformations during the dissolution of ritonavir (RTV) amorphous solid dispersions (ASDs).

methodsRTV ASDs with polyvinylpyrrolidone (PVP), polyvinylpyrrolidone vinyl acetate (PVPVA) and hydroxypropyl methylcellulose acetate succinate (HPMCAS) were prepared at 10-50% drug loading by solvent evaporation. The miscibility of RTV ASDs was studied before and after exposure to 97% relative humidity (RH). Non-sink dissolution studies were performed on fresh and moisture-exposed ASDs. RTV and polymer release were monitored using ultraviolet-visible spectroscopy. Techniques including fluorescence spectroscopy, confocal imaging, scanning electron microscopy (SEM), atomic force microscopy (AFM), differential scanning calorimetry (DSC) and nanoparticle tracking analysis (NTA) were utilized to monitor solid and the solution state phase transformations.

resultsAll RTV-PVP and RTV-PVPVA ASDs underwent moisture-induced amorphous-amorphous phase separation (AAPS) on high RH storage whereas RTV-HPMCAS ASDs remained miscible. Non-sink dissolution of PVP- and PVPVA-based ASDs at low drug loadings led to rapid RTV and polymer release resulting in concentrations in excess of amorphous solubility, liquid-liquid phase separation (LLPS) and amorphous nanodroplet formation. High drug loading PVP- and PVPVA-based ASDs did not exhibit LLPS upon dissolution as a consequence of extensive AAPS in the hydrated ASD matrix. All RTV-HPMCAS ASDs led to LLPS upon dissolution.

conclusionsRTV ASD dissolution is governed by a competition between the dissolution rate and the rate of phase separation in the hydrated ASD matrix. LLPS was observed for ASDs where the drug release was polymer controlled and only ASDs that remained miscible during the initial phase of dissolution led to LLPS. Techniques such as fluorescence spectroscopy, confocal imaging and SEM were useful in understanding the phase behavior of ASDs upon hydration and dissolution and were helpful in elucidating the mechanism of generation of amorphous nanodroplets.

Indexed as

CrystallizationCytochrome P-450 CYP3A InhibitorsDelayed-Action PreparationsDrug LiberationExcipientsHIV Protease InhibitorsHumidityMethylcellulosePhase TransitionPovidoneRitonavirSolubilityVinyl CompoundsCytochrome P-450 CYP3A InhibitorsDelayed-Action PreparationsExcipientsHIV Protease Inhibitorshydroxypropylmethylcellulose acetate succinateMethylcellulosePovidoneRitonavirvinyl acetateVinyl Compoundsamorphous-amorphous phase separationamorphous solid dispersiondissolutionfluorescence spectroscopyliquid-liquid phase separation

Identifiers

PMID28956218
OpenAlexW2759450909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.